Leptin Downregulates Aggrecan through the p38-ADAMST Pathway in Human Nucleus Pulposus Cells

Zheng Li1,9, Xin Yu1,2,9, Jinqian Liang1, William Ka Kei Wu3, Jun Yu3, Jianxiong Shen1*

1Department of Orthopaedic Surgery, Peking Union Medical College Hospital, Peking Union Medical College, Beijing, China, 2State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Xicheng District, Beijing, China, 3Department of Anaesthesia and Intensive Care, The Chinese University of Hong Kong, Hong Kong

Abstract

The mechanistic basis of obesity-associated intervertebral disc degeneration (IDD) is unclear. Aberrant expression of aggrecan and its degrading enzymes ADAMTS-4 and ADAMTS-5 is implicated in the development of IDD. Here, we investigated the effect of leptin, a hormone with increased circulating levels in obesity, on the expression of aggrecan and ADAMTSs in primary human nucleus pulposus (NP) cells. Real-time PCR and Western blots showed that leptin increased the mRNA and protein expression of ADAMTS-4 and ADAMTS-5 and reduced the level of aggrecan in NP cells, accompanied by a prominent induction of p38 phosphorylation. Treatment of NP cells with SB203580 (a p38 inhibitor) abolished the regulation of aggrecan and ADAMTSs by leptin. Knockdown of ADAMTS-4 and ADAMTS-5 by siRNAs also attenuated the degradation of aggrecan in leptin-stimulated NP cells. To conclude, we demonstrated that leptin induces p38 to upregulate ADAMTSs and thereby promoting aggrecan degradation in human NP cells. These results provide a novel mechanistic insight into the molecular pathogenesis of obesity-associated IDD.

Introduction

Musculoskeletal disorders of the spine are leading causes of disability in people younger than 45 years old and result in national economic losses of more than 90 billion dollars per year in China [1]. Disc degeneration of the spine is considered to be one of the underlying factors of low back pain [2]. Intervertebral disc degeneration (IDD) is a multi-factorial process that is influenced by lifestyle, genetic predisposition, comorbidities, and aging [3]. The intervertebral disc has a complex structure with the nucleus pulposus (NP) encapsulated by endplates and the annulus fibrosus [4]. The pathogenesis of IDD is poorly understood, although it is known to be associated with a variety of cellular and biochemical changes. One of the most important biochemical hallmarks of IDD is extensive degradation of extracellular matrix (ECM) [5]. The ECM is constantly synthesized and degraded by disc cells in which the rates are normally in balance. However, the balance is shifted towards degradation in IDD, with alterations in collagen type and a decrease in proteoglycan content, leading to the loss of tissue integrity [6]. To this end, the loss of aggrecan, a major type of proteoglycan, is considered to be an early biochemical abnormality of IDD [7].

Aggrecan, a negatively charged proteoglycan, is a major macromolecular component of ECM. The aggrecan monomer consists of a 250 kDa protein core with chondroitin sulfate and keratan sulfate glycosaminoglycan (GAG) side chains attached [8]. Degradation of aggrecan results in dehydration of the disc, which leads to a reduced resistance to compressive load and a reduction in disc height [9]. In the cartilage, two major aggregcanases, a disintegrin and metalloproteinase with thrombospondin motifs 4 (ADAMTS-4) and 5 (ADAMTS-5), are involved in the breakdown of aggrecan [10]. In addition, both ADAMTSs expression are elevated in the NP of human degenerative disc disease [11]. However, the regulation of ADAMTS-4 and ADAMTS-5 expression in NP cells is unknown.

Obesity is a risk factor for IDD, and recent findings indicate that adiposity rather than the excess in body mass is detrimental to the intervertebral disc [12,13]. The contribution of adiposity-associated metabolic factors to the pathogenesis of intervertebral disc disorders has been the subject of increasing investigations. Leptin, a key cytokine secreted by adipose tissue, has been implicated in many obesity-associated diseases [14]. The serum levels of leptin are about 5 times higher in obese subjects than in normal individuals, with an average of 40 and 8 ng/ml, respectively [15,16]. The major function of leptin is to regulate signals from the central nervous system to inhibit food intake and stimulate energy expenditure. Accumulating data suggests that leptin could play key roles in many other physiological processes, such as lipid metabolism, hematopoiesis, immune function, angiogenesis, reproduction, bone formation and inflammation [17]. As a
mitogenic factor, leptin has been shown to stimulate the proliferation of cancer cells of different tissue origins, including prostate, breast, liver, colon and kidney, via binding to its long isoform leptin receptor (OB-Rb) [18–21]. Interestingly, recent studies also indicate that leptin could regulate cell functions in intervertebral disc tissue which expresses functional leptin receptor [22]. To this end, the expression of OB-Rb is upregulated in advanced osteoarthritis and correlated with the body mass index in patients with IDD [12]. Nevertheless, the role of leptin in ECM remodeling, in particular aggrecan degradation, remains unclear.

The aim of the present study is to investigate the effects of leptin on the expression of aggrecan and its degrading enzymes ADAMTS-4 and ADAMTS-5 as well as the associated cellular mechanisms in human NP cells.

**Materials and Methods**

**Ethics**

All of the experimental protocols were approved by the Clinical Research Ethics Committee of the Peking Union Medical College Hospital. Human lumbar intervertebral disc samples were obtained from patients undergoing discectomy following fully informed written consent of patients.

**Reagents**

The p38 mitogen-activated protein kinase (MAPK) inhibitor SB03580 was purchased from Sigma. All primary antibodies and siRNAs were purchased from Santa Cruz Biotechnology.

**Isolation and culture of human NP cells**

The human NP cells were dissected from patient underwent surgeries for idiopathic scoliosis (n = 4; average age 20±1.83, range 18–22 years, and Thompson degeneration grade 1). NP cells were isolated and cultured as previously described [12,13]. After isolation, NP cells were resuspended in DMEM containing 10% fetal bovine serum (FBS; GIBCO, NY, USA), 100 μg/ml streptomycin, 100 U/ml penicillin and 1% L-glutamine, and then incubated at 37°C in a humidified atmosphere with 95% (v/v) air and 5% (v/v) CO2. The confluent cells were detached by trypsinization, seeded into 35-mm tissue culture dishes in complete culture medium (DMEM supplemented with 10% FBS, 100 μg/ml streptomycin, 100 U/ml penicillin) in a 37°C, 5% (v/v) CO2 environment. The medium was changed every 2 days. The second passage was used for subsequent experiments.

**Cell transfection**

ADAMTS-4 siRNA, ADAMTS-5 siRNA or control siRNA pool was transfected into human NP cells by DharmaFECT1 Reagent (Dharmacon, TX, USA) at a final oligonucleotide concentration of 10 nmol/L according to the manufacturer’s instructions. For each cell transfection two or three replication experiments were performed.

**Western blots**

Western blots were performed using standard methods. Proteins were separated on 10% SDS-PAGE, and then transferred to PVDF membranes (Amersham, Buckinghamshire, UK). Membranes were blocked overnight with 5% (w/v) non-fat dried milk and incubated for 2 h with anti-aggrecan antibody, anti-ADAMTS-4 antibody, anti-ADAMTS-5 antibody, anti-p38 antibody or anti-p-p38 antibody at 1:1000 dilution or anti-GAPDH antibody (Proteintech,Chicago, USA) at 1:50,000 dilution. After washing with TBST (10 mM Tris, pH 8.0, 150 mM NaCl, and 0.1% Tween20), the membranes were incubated for 2 h with goat anti-rabbit antibody (zsgb-bio, Beijing, China) at 1:5000 or 1:50000 dilution (for GAPDH).

**Real-time RT-PCR**

Total RNA was extracted from NP cells using TRizol reagent (Invitrogen, CA, USA) according to the manufacturer’s instructions. RNA was isolated with chloroform and isopropanol, washed with ethanol, and dissolved in water. Quantification of RNA was based on spectrophotometric analysis at 260/280 nm with values between 1.8 and 2.0 confirmed the purity of the RNA samples. A 2-μg sample of total RNA was reverse-transcribed with 200 U of MMLV reverse transcriptase (Invitrogen) using Oligo(dT) primers in a 20 μL reaction mixture following the manufacturers’ instructions. Relative transcript levels of aggrecan, ADAMTS-4 and ADAMTS-5 were determined by real-time PCR using the iQ5 Real-Time PCR Detection System (Bio-Rad, California, USA). The real-time PCR reaction was composed of 1 x SYBR Green fluorescent dye (Takara, Dalian, China), 1 μl forward primers (10 μM), 1 μl reverse primers (10 μM), 1 x iQ PCR mix, 1 μl cDNA. The sequences of the specific primers are shown in Table 1. To produce the melting curve, the reactions were subject to one step at 95°C for 30 s followed by 43 cycles of 95°C for 5 s, 60°C for 10 s, and 72°C for 30 s. The relative gene expression was assessed by the ΔΔCt method. GAPDH was used as an internal control.

**Statistical analysis**

Results were expressed as means ± SD of multiple experiments. Statistical analysis was performed with Student’s t-test for comparison between two groups. P values less than 0.05 were considered statistically significant.

**Results**

**Leptin inhibited aggrecan expression**

Treating NP cells with leptin (10 ng/ml) significantly reduced aggrecan mRNA levels in a time-dependent manner, with the maximal response at 48 h. Dose-response analysis demonstrated that leptin at the concentration of 1000 ng/ml at the 48 h time point could maximally reduced aggrecan mRNA levels (Fig. 1A). To further investigate whether the reduction in aggrecan mRNA was paralleled by a decrease in aggrecan protein level, Western blot was performed (Fig. 1B). Similar to the effect of leptin on aggrecan mRNA, time-dependent reduction in aggrecan protein expression by leptin was observed.

**Leptin promoted ADAMTS-4 and ADAMTS-5 expression**

As shown in Fig. 2, treating NP cells with leptin (10 ng/ml) significantly increased ADAMTS-4 and ADAMTS-5 mRNA levels in a time-dependent manner, with the maximal response both at 40 h. Dose-response analysis revealed that the maximal response to leptin (1–1000 ng/ml) occurred both at the concentration of 100 ng/ml (48 h) (Fig. 2A). Western blot was then performed to further investigate whether the induction of ADAMTS-4 and ADAMTS-5 by leptin occurred at protein level. Results showed that leptin could time-dependently increased ADAMTS-4 and ADAMTS-5 protein expression (Fig. 2B).

**Leptin induced p38 MAPK phosphorylation in human NP cells**

Previous studies have shown that p38 MAPK could regulate aggrecan expression in chondrocytes [23]. As shown in Fig. 3A, leptin time-dependently increased p38 phosphorylation of without...
altering the total protein levels in human NP cells. The stimulation of p38 phosphorylation could be observed as early as 5 min after leptin (10 ng/ml) promotion. These findings indicate that leptin could readily activate p38 MAPK pathways in human NP cells.

Pharmacological inhibition of p38 MAPK pathways prevented the regulation of aggrecan, ADAMTS-4 and ADAMTS-5 by leptin

To examine the possible involvement of p38 MAPK pathway in mediating the effects of leptin on ECM remodeling, NP cells were treated with or without SB203580, in the absence or presence of leptin. Western blot and Real-time RT-PCR analysis show that SB203580 blocked leptin-induced alterations in aggrecan, ADAMTS-4 and ADAMTS-5 protein and mRNA expression (Fig. 3B and 3C).

ADAMTS-4 and ADAMTS-5 silencing attenuated leptin-induced aggrecan degradation in NP cells

We examined the effect of silencing ADAMTS-4 and ADAMTS-5 expression on aggrecan degradation in human NP cells. ADAMTS-4 and -5 protein levels in the NP cells were significantly reduced by transfection with respective siRNA (Fig. 4A). We then used Western blot to measure aggrecan protein levels in ADAMTS-silenced NP cells. Suppression of ADAMTS-4 and -5 expression significantly restored aggrecan protein expression, indicating the contribution of these two aggrecanases to leptin-induced aggrecan degradation in NP cells (Fig. 4B and 4C).

Discussion

Increasing epidemiological evidence has supported the close association between obesity and IDD [24]. The cellular and

---

**Table 1. Primer sequence.**

| Name   | Sequence (5'-3') |
|--------|-----------------|
| GAPDH  | Forward: TCAACGACCACCTTTGTCAGACTT  <br> Reverse: GGTGTCAGGGGTCTTAC |
| aggrecan | Forward: CTACCAGTGACGCGCCCTGA  <br> Reverse: CGTGCCAGATGTAACCATAAC |
| ADAMTS-4 | Forward: ACTGTGCTGTGCCAGATGACA  <br> Reverse: TCACTGTTAAGGATAGGCTTT |
| ADAMTS-5 | Forward: GGACCTACAGAAAGCAAGATC  <br> Reverse: GCCGGGAACACAGGAGTAC |

---

**Figure 1. Leptin inhibited aggrecan expression.** (A) Leptin (10 ng/ml) significantly inhibited aggrecan transcription in a time-dependent manner, with a maximal response both at 48 h. Dose-dependent studies demonstrated a maximal response to leptin (1–1000 ng/ml) was at the concentration of 1000 ng/ml at the 48 h time point. (B) The effect of leptin on aggrecan protein expression was detected with western blotting analysis using GAPDH as an internal control. Error bars represent standard deviation.

doi:10.1371/journal.pone.0109595.g001
molecular mechanism of obesity-related IDD, however, remains unclear. In our study, leptin, a hormone with increased circulating levels in obese patients, has been implicated in the pathogenesis of obesity-related IDD [22,25]. We first demonstrated that leptin directly inhibited aggrecan expression and induced ADAMTS-4 and ADAMTS-5 mRNA and protein expression. These alterations were dependent on p38 activation in NP cells. Importantly, both ADAMTS-4 and -5 were functionally involved in leptin-induced aggrecan degradation in human NP cells. These results indicated that leptin could impair aggrecan expression via induction of ADAMTS-4 and ADAMTS-5 in NP cells and thereby contributing to the pathogenesis of IDD.

The ECM provides both mechanical and biochemical signals to NP cells to regulate their survival, morphology and differentiation. Current evidence implicates the loss of ECM in intervertebral disc during IDD in which the loss of proteoglycans, predominantly aggrecan, is considered as an early indicator of IDD. In this respect, Sobajima et al. reported that gene expression of aggrecan was abundant in the non-degenerated, healthy IVD, but its expression steadily declined after annular stab. Although the functional importance of aggrecan secretion has been established, the molecular mechanisms controlling aggrecan turnover in cells of the normal and the degenerated disc are not well understood. Here we found that leptin could enhance aggrecan degradation, which might play a detrimental role in obese-associated IDD.

Aggrecanases are proteinases that cleave a particular glutamyl bond in the interglobular domain of aggrecan, thereby releasing the bulk of the aggrecan molecule from the tissue [26]. Tortorella

Figure 2. Leptin promoted ADAMTS-4 and ADAMTS-5 expression. (A) The effect of leptin on ADAMTS-4 and ADAMTS-5 mRNA expression assessed using Real-time RT-PCR. For the dose-dependent studies, NP cells were treated with either medium only or varying concentrations of leptin (1–1000 ng/ml) for 24 h. For the time-dependent studies, NP cells were treated with either medium only or leptin (10 ng/ml) for varying time intervals (0–72 h). (B) The effect of leptin on ADAMTS-4 and ADAMTS-5 protein expression was detected with western blotting analysis using GAPDH as an internal control. Error bars represent standard deviation. The medium was changed every day. *p<0.05, **p<0.01, and ***p<0.001. doi:10.1371/journal.pone.0109595.g002
et al. identified the first aggrecanase known as aggrecanase 1 or ADAMTS-4 [27]. Later that year, the same research team identified the second enzyme aggrecanase 2, which is now known as ADAMTS-5 [28]. ADAMTS-4 and -5 play a key role in aggrecan degradation [29]. Emerging studies have demonstrated the importance of both ADAMTS-4 and -5 in the degeneration of intervertebral disc. Demircan et al. reported that ADAMTS-4 and -5 expression could be detected in herniated intervertebral disc [30,31]. Pockert et al. also found that the mRNA and protein levels of these two aggrecanases were elevated in degenerated human intervertebral disc samples compared to nondegenerated controls [7]. Previous studies showed that ADAMTS-4 and -5 could be upregulated by inflammatory cytokines, such as tumor necrosis factor (TNF)-α and interleukin (IL)-1β, and such regulation was required for cytokine-dependent aggrecan degradation in human NP cells [10]. In the present study, leptin induced a strong expression of ADAMTS-4 and -5 at the mRNA and protein levels in NP cells where their knockdown by siRNAs remarkably inhibited leptin-induced aggrecan loss in human NP cells. These data presented here strongly suggest a crucial role for leptin-induced ADAMTS-4 and -5 expressions in the breakdown of aggrecan in NP cells during IDD. However, it is noteworthy that leptin by itself reduced aggrecan mRNA levels whereas ADAMTS-4/5 in theory should contribute to aggrecan proteolysis but not to its regulation at the transcriptional level. Nevertheless, contrary to our expectation, ADAMTS-4/5 knockdown also abrogated the repressive effect of leptin on aggrecan mRNA expression, indicating that ADAMTS-4/5 might be required for mediating the transcription-dependent effects of leptin. This finding is concordant with previous data supporting that ADAMTSs may not only function as extracellular effectors, but also play a role in the modulation of intracellular signaling [32].

Aside from investigating the direct effects of leptin on ADAMTS-4 and -5 expression and aggrecan degradation, we delineated the involvement of p38 MAPK pathway whose roles in leptin signaling and aggrecan degradation have been established in other biological contexts [33,34]. We found that leptin potently induced p38 phosphorylation in human NP cells. Previous evidences indicated that p38 signaling could control ADAMTS-4 and ADAMTS-5 expression in chondrocytes [35]. To this end, Tian et al. reported that TNF-α and IL-1β could modulate ADAMTS-4 and -5 expression through p38 [10]. In line with this previous finding, we also observed that the p38 MAPK inhibitor SB203580 could attenuate aggrecan degradation and ADAMTS-4 and ADAMTS-5 mRNA and protein induction caused by leptin. Importantly, our data suggest that leptin-induced aggrecan downregulation could be contributed by both downregulation of aggrecan mRNA as well as increased degradation through ADAMTSs. In this regard, p38 has also been shown to mediate the downregulation of aggrecan mRNA in chondrocytes treated with IL-1β. However, it must be pointed out that TNF-α and IL-1β are known to change ADAMTS-4/5 expression within a few hours [36] whereas leptin downregulated aggrecan or upregulated ADAMTS-4/5 only after 12-24 hour in the present study. It raised the possibility that the observed effects may be secondary to leptin signaling. To this end, leptin has been shown to up-regulate the production of pro-inflammatory cytokines, including TNF-α, in macrophages [37]. Whether the upregulation of pro-inflammatory cytokines is required for leptin-induced ADAMTS-4/5 expression and aggrecan degradation, nevertheless, warrants further investigation. In addition to p38 MAPK, our previous data indicated leptin could induce STAT3 signaling in NP cells where pharmacological inhibition of JAK2, the upstream regulator of STAT3, could inhibit leptin-induced cell proliferation [36].
order to identify more druggable targets for obesity-associated IDD, it would be interesting to delineate if JAK2/STAT3 signaling is also involved in leptin-induced ADAMTS-4/5 upregulation and aggrecan downregulation. Although in vitro data supports that leptin-induced aggrecan downregulation is implicated in obesity-associated IDD, further experiments are needed to differentiate the effect of hyperleptinemia from those arising from other metabolic deregulations in obesity. Determining ADAMTS-4/5 and aggrecan expression in NP cells of obese db/db or ob/ob mice, which are deficient in leptin signaling, would definitely provide a clearer picture. Moreover, it would be valuable to measure ADAMTS-4/5 and aggrecan expression in mice injected with leptin, either acute or long-term, to establish the relationship between hyperleptinemia and ECM imbalance in NP cells in vivo. In summary, we provide the first evidence that leptin could induce ADAMTS-4 and -5

Figure 4. ADAMTS-4 and ADAMTS-5 silencing attenuated leptin-induced aggrecan degradation in NP cells. (A) The protein expression of ADAMTS-4 and -5 were detected with western blotting analysis using GAPDH as an internal control. (B) NP cells were treated with control siRNA (siRNA-con), 10 ng/ml leptin, siRNA-ADAMTS-4 or siRNA-ADAMTS-5 for 48 h. The amounts of aggrecan protein were detected with western blotting analysis using GAPDH as an internal control. The signal in each lane was quantified using ImageJ software and the ratio of aggrecan to GAPDH was determined. (C) Aggrecan mRNA expression were detected with Real-time RT-PCR analysis using GAPDH as an internal control. Error bars represent standard deviation.

doi:10.1371/journal.pone.0109595.g004
expression and thereby promoting aggrecan degradation in human NP cells. Leptin could also directly reduce aggrecan mRNA expression and both actions could be mediated by p38 activation. These data suggest that p38 and ADAMTSs are potential targets for pharmacological intervention in obesity-associated IDD.

References

1. Speed C (2004) Low back pain. BMJ 328: 1119–1121.
2. Roberts S, Evans H, Trivedi J, Menage J (2006) Histology and pathology of the human intervertebral disc. J Bone Joint Surg Am 88 Suppl 2: 10–14.
3. Adams MA, Roughley PJ (2006) What is intervertebral disc degeneration, and what causes it? Spine (Phila Pa 1976) 31: 2151–2161.
4. Minogue BM, Richardson SM, Zeef LA, FrementeyJ, Hoyland JA (2010) Characterization of the human nucleus pulposus cell phenotype and evaluation of novel marker gene expression to define adult stem cell differentiation. Arthritis Rheum 62: 3905–3915.
5. Hayes AJ, Benjamin M, Ralphe JR (2001) Extracellular matrix in development of the intervertebral disc. Matrix Biol 20: 107–121.
6. Hsieh AH, Twomey JD (2010) Cellular mechanobiology of the intervertebral disc: new directions and approaches. J Biomech 43: 137–145.
7. Pockert AJ, Richardson SM, Le Maitre CL, Lyon M, Deakin JA, et al. (2009) Modified expression of the ADAMTS enzymes and tissue inhibitor of metalloproteinases 3 during human intervertebral disc degeneration. Arthritis Rheum 60: 482–491.
8. Ashberg A (2012) The different roles of aggrecan interaction domains. J Histochim Cytochem 60: 987–996.
9. Cabrera M, Endres M, Abbashi A, Zelencscher M, Blechschmidt C, et al. (2013) Effect of degeneration on gene expression of chondrogenic and inflammatory marker genes of intervertebral disc cells: a preliminary study. J Neurosurg Sci 57: 307–316.
10. Tian Y, Yuan W, Fujita N, Wang J, Wang H, et al. (2013) Inflammatory cytokines associated with degenerative disc disease control aggrecanase-1 (ADAMTS-4) expression in nucleus pulposus cells through MAPK and NF-kappaB. Am J Pathol 182: 2130–2321.
11. Hartvangder T, Chan SC, Bahenberg G, Richards PJ, Gantenbein-Ritter B (2013) Assesment of the Matrix Degenerative Effecits of MMP-3, ADAMTS-4 and HTRA1 injected into a bovine Intervertebral Disc Organ Culture Model. Spine (Phila Pa 1976).
12. Li Z, Shen J, Wu WK, Yu X, Liang J, et al. (2013) The role of leptin on the organization and expression of cytoskeleton elements in nucleus pulposus cells: J Orthop Res 31: 847–857.
13. Li Z, Shen J, Wu WK, Yu X, Liang J, et al. (2012) Leptin induces cyclin D1 expression and proliferation of human nucleus pulposus cells via JAK/STAT, P3K/Akt and MEK/ERK pathways. PLoS One 7: e53176.
14. Friedman JM, Halaas JL (1995) Leptin and the regulation of body weight in mammals. Nature 375: 763–770.
15. L’Allier D, Schmitt S, Rousson V, Brabant G, Gasser T, et al. (2002) Associations between body mass, leptin, IGF-1 and circulating adrenal androgens in children with obesity and premature adrenarche. Eur J Endocrinol 146: 347–354.
16. Maffei M, Halaas J, Ravniss E, Prazley RE, Lee GH, et al. (1995) Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med 1: 1155–1161.
17. Denver RJ, Bonett RM, Boone GC (2011) Evolution of leptin structure and function. Neuroendocrinology 94: 31–38.
18. Hou N, Lao JD (2011) Leptin and cardiovascular diseases. Clin Exp Pharmacol Physiol 38: 905–913.
19. Jain M, Budinger GR, Lo A, Urlich D, Rivera SE, et al. (2011) Leptin promotes fibroproliferative acute respiratory distress syndrome by inhibiting perezonx, proliferator-activated receptor-gamma. Am J Respir Crit Care Med 183: 1490–1498.
20. Carlton ED, Demas GE, French SS (2012) Leptin, a neuroendocrine mediator of immune responses, inflammation, and sickness behaviors. Horm Behav.
21. Housa D, Housova J, Vernerova Z, Haluzik M (2006) Adipocyctokines and cancer. Physiol Res 55: 235–244.
22. Zhao CQ, Liu D, Li H, Jiang LS, Dai LY (2008) Expression of leptin and its functional receptor on disc cells: contribution to cell proliferation. Spine (Phila Pa 1976) 33: E858–864.
23. Radou J, Bossehnhoff AK, Grassel S, Wall W, Schubert TE (2006) p38MAPK mediates IL-1-induced down-regulation of aggrecan gene expression in human chondrocytes. Int J Mol Med 17: 661–668.
24. Samartzes D, Karppinen J, Mok F, Feng DY, Lak KD, et al. (2011) A population-based study of juvenile disc degeneration and its association with overweight and obesity, low back pain, and diminished functional status. J Bone Joint Surg Am 93: 662–670.
25. Gruber HE, Ingram JA, Hoelcher GL, Hanley EX Jr. (2007) Leptin expression by annulus cells in the human intervertebral disc. Spine J 7: 437–443.
26. Bateman JF, Rowley L, Belluccios D, Chan B, Bell K, et al. (2013) Transcriptsomics of wild-type mice and mice lacking ADAMTS-5 activity identifies genes involved in osteoarthritis initiation and cartilage destruction. Arthritis Rheum 65: 1547–1560.
27. Tortorella MD, Burn TC, Pratta MA, Abbaszade I, Hollis JM, et al. (1999) Purification and cloning of cingrellase-1: a member of the ADAMTS family of proteins. Science 284: 1664–1666.
28. Abbaszade I, Liu RX, Yang F, Rosenfeld SA, Ross OH, et al. (1999) Cloning and characterization of ADAMTS1, an aggrecanse from the ADAMTS family. J Biol Chem 274: 23443–23450.
29. Song RH, Tortorella MD, Mallat AM, Abston JT, Yang Z, et al. (2007) Aggrecan degradation in human articular cartilage explants is mediated by both ADAMTS-4 and ADAMTS-5. Arthritis Rheum 56: 575–583.
30. Demircan K, Hirohata S, Nishida K, Hatipoglu OF, Ooshishi T, et al. (2005) ADAMTS-9 is synergistically induced by interleukin-1beta and tumor necrosis factor alpha in OUMS-27 chondrosarcoma cells and in human chondrocytes. Arthritis Rheum 52: 1451–1460.
31. Akhatib B, Omerferd P, Gervi R, Ouellet J, Jarzem P, et al. (2013) Chondroadherin fragmentation mediated by the protease HTRA1 distinguishes human intervertebral disc degeneration from normal aging. J Biol Chem 298: 19280–19287.
32. Freitas VM, do Amaral JB, Silva TA, Santos ES, Mangone FR, et al. (2013) Decreased expression of ADAMTS-1 in human breast tumors stimulates migration and invasion. Mol Cancer 12: 2.
33. Thompson KJ, Lau KN, Johnson S, Martinie JB, Iannitti DA, et al. (2011) Leptin inhibits hepatocellular carcinoma proliferation via p38-MAPK-dependent signalling. HPB (Oxford) 13: 225–233.
34. Liang C, Xiao J, Deng Z, Song C, Zhang J, et al. (2013) Leptin attenuates lipopolysaccharide-induced apoptosis of thymocytes partially via down-regulation of p38MAPK activation. Int Immunopharmacol 15: 620–627.
35. Saito T, Nishida K, Furumato T, Yoshida A, Ozawa M, et al. (2013) Histone deacetylase inhibitors suppress mechanical stress-induced expression of RUNX-2 and ADAMTS-5 through the inhibition of the MAPK signaling pathway in cultured human chondrocytes. Osteoarthritis Cartilage 21: 165–174.
36. Abbasah SA, Lian CX, Ramurrunt AK, Goh JC, Wong HK (2011) Fusion Performance of Low Dose rhBMP-2 and BMSCs in Biodegradable Scaffold: A Comparative Study in a Large Animal Model of Anterior Lumbar Interbody Fusion. Spine (Phila Pa 1976).
37. Loffreda S, Yang SQ, Liu HZ, Karp CL, Bremgman ML, et al. (1998) Leptin regulates proinflammatory immune responses. FASEB J 12: 57–65.

Acknowledgments

We thank Prof. Hong Zhao and Prof. Shugong Li for assistance in disc samples collection. Finally, we would like to thank all the volunteers who took part in this study.

Author Contributions

Conceived and designed the experiments: ZL XY JL JS. Performed the experiments: ZL XY. Analyzed the data: ZL XY. Contributed reagents/materials/analysis tools: ZL. Wrote the paper: ZL XY WKKW JS JY.